RBC Capital maintains Mirum Pharmaceuticals at Outperform, keeps price target at $155

What happened

RBC Capital maintained its Outperform rating on Mirum Pharmaceuticals and kept its price target at $155. The article says that target implies 78.1% upside from the November 3 closing price of $87.03; five recent analyst targets ranged from $145 to $202.

Confirmed

Global impact / market context

The unchanged rating and target do not represent a new forecast from RBC, but they reinforce its positive view of Mirum. Analyst targets can shape investor expectations, although they are estimates rather than guaranteed outcomes and do not establish what the share price will do.

Analyst inference

The article lists four other recent ratings, all maintained, with targets spanning $145 to $202; RBC’s $155 target sits within that range. This spread shows analysts differ on valuation, which can influence how investors weigh the company’s prospects.

Analyst inference

What to watch

1. Compare future company updates with the assumptions behind RBC’s unchanged $155 target; the article provides no details on those assumptions or any new company developments. Analyst inference
2. Watch for whether RBC changes its rating or target in a later note, since either change would show its view has shifted from the position reported here. Analyst inference
3. The article reports four other recent analyst targets from $145 to $202, providing a reference range for judging whether later analyst estimates converge or diverge. Confirmed

Evidence

• Original source link unavailable